LONE TREE, Colo., July 8, 2025 /PRNewswire/ -- Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, today announced the U.S Food and Drug Administration (FDA) approval of ...

Cochlear Limited, which creates implantable hearing devices, has taken a technological leap forward with a device that syncs up with various Apple products. The Nucleus 7 Sound Processor, which was ...

In celebration of International Cochlear Implant Day, Cochlear North America is proud to announce the recipients of the 2026 Cochlear Academic Scholarships. This year, eight exceptional students, who ...

Cochlear reaffirmed guidance for FY 2025 underlying net profit between $410 million and $430 million, though it expects to achieve the lower end of this range. The revision is driven by weaker ...

When the parts of the ear that transmit sound to the auditory nerve are damaged—as they often are in the severely deaf—a hearing aid that merely amplifies sound offers little assistance. Today, more ...

Cochlear, the global leader in implantable hearing solutions, today launched the Cochlear™ Nucleus® Nexa® System - the ...

Thank you for standing by, and welcome to the Cochlear Limited Half Year 2025 Results Analyst and Media Briefing. All participants are in listen-only mode. There will be presentation, followed by a ...

Cochlear Ltd. engages in the provision of implantable hearing solutions. The firm operates through the following segments: Cochlear Implants, Services, and Acoustics. The Cochlear Implants segment ...

Cochlear Ltd. and Sensorion SA have published encouraging results on the combination of a molecule with a cochlear implant. Their proof-of-concept phase 2a study involved the combination of an orphan ...